In preclinical models of PD, sigma-1 receptor activation has been associated with improved mitochondrial function, reduced microglial activation and decreased dopaminergic cell loss, as well as an increase in brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) [60]. The gene discussed is GDNF; the disease is Parkinson disease.